Anisop are delighted to have been awarded up to $1 million through the Australian Government’s Medical Research Future Fund BioMedTech Horizons program, operated by MTPConnect. This funding provides a critical boost to realise commercialisation of Anisop’s breakthrough infection technology for medical implants. Dr Dan Barker, Anisop’s Chief Medical and Technology Officer states “Infection prevention is the most important unmet need for medical devices such as dental and orthopaedic implants. We have acquired the intellectual property rights to commercialise a novel surface treatment for titanium implants that is transformational, safe, and effective. The support provided from the BioMedTech Horizons program provides critical funding to support the necessary tests and experiments to translate this Australian technology from bench-top to bedside.